Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pipobroman
- Development stage
- Unknown
- Lead developer
- Roczniki Chemii
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pipobroman is an antineoplastic agent and a piperazine derivative structurally related to DNA alkylating agents. It is primarily used in the treatment of polycythemia vera and essential thrombocythemia. The drug likely acts as an alkylating agent, disrupting DNA synthesis by alkylating DNA, which leads to cell death. Pipobroman has demonstrated high clinical activity in its primary indications, with response rates exceeding 90% within three months of therapy. It is administered orally and has been marketed under the brand names Vercyte and Vercite in France and Italy[2][4][6].
- Brand names
- VercyteVerciteAmedel
- Other names
- 1,1'-(Piperazine-1,4-diyl)bis(3-bromopropan-1-one)pipobroman
02
Targets
DNA
Beyond the preview
Go deeper on pipobroman.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pipobroman.